Dana Farber | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana Farber

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

September 14, 2021

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.

NEJM Data Underscores DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 07, 2021

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

FDA Grants Priority Review to Abatacept for Prevention of Acute GVHD

August 23, 2021

The FDA has granted a priority review designation to a supplemental biologics license application seeking the approval of abatacept for the prevention of moderate to severe acute graft-versus-host disease in patients aged 6 years and older who are receiving unrelated donor hematopoietic stem cell transplantation.

Future of Care for PCNSL Relies on Adapting Personalized Approaches

August 23, 2021

Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.

MRD Negativity Moves Into the Spotlight as a Potential Surrogate End Point in Multiple Myeloma

August 23, 2021

Ongoing research efforts are pushing to establish minimal residual disease negativity as a surrogate end point for patient outcomes in multiple myeloma clinical trials, and MRD assessment is becoming an increasingly utilized tool to inform real-world clinical decisions.

Clonal Hematopoiesis Confers Substantial Risks in Healthy Individuals and Patients with Cancer

August 20, 2021

Peter G. Miller, MD, PhD, discusses the characteristics and risks associated with clonal hematopoiesis and risk-stratification efforts for patients with cancer who are at risk of developing therapy-related secondary malignancies from clonal hematopoiesis.

Cancer Screenings Recover From Height of COVID-19 Pandemic, But Disparities Remain

August 19, 2021

Chris Labaki, MD, and Quoc-Dien Trinh, MD, discuss their research on the decline in cancer screenings during the height of the COVID-19 pandemic, the recovery of these tests, and potential existing disparities to be addressed.

DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19

August 19, 2021

Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests, its link with potential racial disparities from the COVID-19 pandemic, and how the community can continue to emphasize the importance of cancer screening while working to close these disparities in cancer care.

Dana-Farber Cancer Institute Establishes the David Liposarcoma Research Initiative

August 19, 2021

The David Liposarcoma Research Initiative will spearhead groundbreaking research into liposarcoma at Dana-Farber and external collaborating partner institutions, with the aim of transforming the treatment of this rare, underfunded, and understudied disease in order to improve care of patients through research.

Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions

August 10, 2021

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.